Merck shares fall 9% despite earnings beat, strong demand for top drugs like Keytruda
The drugmaker raised its full-year sales forecast to $63.4 billion to $64.4 billion on increased demand for key products, particularly oncology treatments.
The drugmaker raised its full-year sales forecast to $63.4 billion to $64.4 billion on increased demand for key products, particularly oncology treatments.
